TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - Diagnosis of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) as per Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text revision (DSM-IV TR)- Have had at least 2 hospitalizations or 2 clinical worsening of symptoms, over the past 2 years because of deteriorating adherence - Is currently receiving treatment with an antipsychotic per local product label guidelines, and has a history in the last 5 years of a satisfactory response (minimum of 6 weeks) to oral antipsychotics (excluding clozapine) - On monotherapy antipsychotic treatment as per local product label guidelines, at Baseline -Female participants must be surgically sterile, or practicing an effective method of birth control before entry and throughout the study, and have a negative urine pregnancy test at screening before study entry Exclusion Criteria: - Participants with a primary DSM-IV TR Axis I diagnosis other than schizophrenia - Female participants who are currently pregnant or breastfeeding or planning a pregnancy within 2 years of trial start - Have a serious, unstable and untreated medical illnesses, such as vascular or cardiovascular disease, history of liver or kidney disease, significant cardiac (having to do with the heart), pulmonary (having to do with the lungs), gastrointestinal, endocrine, neurological (pertaining to the nervous system) or metabolic disturbances - At significant risk of suicide or violence at study start - Evidence of substance dependence (except for nicotine and caffeine dependence) according to DSM-IV TR criteria diagnosed in the last month prior to entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Risperidone long-acting injection (LAI) (Type: EXPERIMENTAL): Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.
- Oral atypical Antipsychotic (Type: ACTIVE_COMPARATOR): Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intramuscular Injections of Botulinum Toxin in Lateral Pterygoid Muscle in the Treatment of Temporomandibular Dysfunctions: Studying the Interest of MRI Guidance and Ultrasound Guidance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients suffering from muscular TemporoMandibular Dysfunctions (TMD) with clinical diagnosis: myofascial pain, limited opening of the mouth, articular noise.~* \>= 18 years old~* with signed informed consent form~Exclusion Criteria:~* articular TMD: arthritis or other inflammatory disease of temporomandibular joint, arthrosis, bone deformation, previous fracture of condylar area ;~* electromyographic hypoactivity, pure muscular diseases ;~* oro-mandibular dystonia ;~* botulinum toxin allergy,~* risk of bleeding~* recent or active infection~* intercurrent antibiotic treatment (drug interaction) ;~* vaccination during the 15 days preceding the injection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRI guidance (Type: EXPERIMENTAL): Injections of botulinum toxin performed using MRI guidance
- Ultrasound guidance (Type: EXPERIMENTAL): Injections of botulinum toxin performed using ultrasound guidance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Quilting Sutures on Post-operative Drainage After Mastectomy and/or Axillary Lymph Node Dissection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years-old female patients~* mastectomy alone, mastectomy and sentinel, mastectomy and axilla, axilla and tumorectomy or axilla alone~* patients with histo- or cytology proven breast cancer Union for International Cancer Control's (UICC)/American Joint Committee on Cancer (AJCC) stage I-III~* Fluency in either German or French~* The EQ-5D and BPI questionnaires must be completed by the patient at registration~* Patient has given written informed consent before registration.~Exclusion Criteria:~* Bilateral operation or reconstruction~* Psychiatric disorder precluding understanding of information on trial related topics, giving informed consent and/or filling out the questionnaires~* Pregnancy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): quilting
- Arm B (Type: ACTIVE_COMPARATOR): conventional suture

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: pCHIP: Prostate Cancer Health Impact Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Established Prostate Cancer Group:~Inclusion Criteria:~* Participant must be designated male at birth~* Self-identified AA or H/L~* Be 18 years of age or older~* Fluent in English or Spanish~* Able to provide informed consent.~Exclusion Criteria:~* Patients or shared decision makers with cognitive or sensory impairment which impede their ability to provide informed consent as determined by consenting individual or documented in the medical record.~At Risk of Prostate Cancer Group:~Inclusion Criteria:~* Participant must be designated male at birth~* Self-identified AA or H/L~* Be 18 years of age or older~* Have stage I-III PCa, not yet begun cancer treatment~* Have no evidence of progressive disease or second primary cancer~Exclusion Criteria:~* Men who have already begun cancer treatment~* Have evidence of progressive disease~* Second primary cancer

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Established Prostate Cancer Group (Type: None): Established Prostate Cancer Group will consist of a qualitative study of 12 semi-structured interviews with self-identified AA patient undergoing prostate treatment (stages I-III) (N-12 patients) and 12 semi-structured interviews with H/L patient undergoing prostate treatment (stages I-III) (N=12 patients) at NYPH Queens and NYPH-BM. Interview content will focus on psycho-social and socio-cultural factors associated with prostate cancer decision making, social support, and physician-patient communication.
- At Risk of Prostate Cancer Group (Type: None): At Risk of Prostate Cancer Group will recruit 58 self-identified AA or H/L men at risk of prostate cancer (stages I-III) receiving care at NYPH-Queens and NYPHQ (29 at each hospital) to participate in the evaluation of the tailored DNI intervention. Men who consent to participate in the study will complete a baseline survey. After biopsy appointment, participants with a negative Prostate Cancer biopsy will receive a study closure phone call, ending study participation.~Participants with positive Prostate Cancer biopsy will proceed with study procedures and be randomly assigned to decision navigation intervention (DNI) or standard of care (SOC). Participants with a positive Prostate Cancer biopsy will be followed for 6 months and complete assessments at 2 weeks, 1 month, and 6 months (close of the study).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dexmedetomidine During Weaning From Analgesia and Sedation in PICU (TIP-15-01)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Continuous analgesic and sedative endovenous treatment for at least 5 days~* Invasive or non-invasive mechanical ventilation~* Clinical conditions that allow by clinical judgment the start of analgosedation weaning~* Post-natal age ≥ 7 days and PMA beyond the 37 weeks~* Written informed consent obtained~Exclusion Criteria:~* Hemodynamic instability~* Cardiac bundle-branch block of 2 or 3 degree~* Hypersensitivity to the alpha-agonists~* Persistent fever of unknown origin or sensitivity to malignant hyperthermia~* Use of alpha-agonist (clonidine or dexmedetomidine) in the last 30 days

- Gender: ALL
- Minimum Age: 7 Days
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): Dexmedetomidine 100 mcg/ml concentrate solution. Continuous iv infusion. Start dose 0.4 mcg/kg/h, increases by 0.2 mcg/kg/h until 0.8 mcg/kg/h (half dose for neonates). If withdrawal symptoms appear the dose can be increased to a maximum of 1.4 mcg/Kg/h.
- Placebo (Type: PLACEBO_COMPARATOR): saline solution for IV infusion. The administration of infusion will follow the experimental drug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of MRT or, neuroblastoma or in dose escalation part, other tumors with documented evidence of D-cyclin-CDK4/6-INK4a-Rb pathway abnormalities (dose escalation part only),~* Patients with CNS disease should be on stable doses of steroids for at least 7 days prior to first dose of LEE011 with no plans for escalation.~* In expansion part, patients must have at least one measurable disease as defined by RECIST v1.1.~* Patients must have a Lansky (≤ 16 years) or Karnofsky (\> 16 years) score of at least 50.~Exclusion Criteria:~* Prior history of QTc prolongation or QTcF \> 450 ms on screening ECG.~* Patients with the following laboratory values during screening:~  * Serum creatinine \> 1.5 x upper limit of normal (ULN) for age~ * Total bilirubin \>1.5 x ULN for age~ * Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) \> 3 x ULN for age; aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase(SGOT) \> 3 x ULN for age except in patients with tumor involvement of the liver who must have AST/SGOT and ALT/SGPT ≤ 5 x ULN for age. For the purpose of this study, the ULN for SGPT/ALT is 45 U/L.~* Patients who are currently receiving treatment with agents that are metabolized predominantly through CYP3A4/5 and have a narrow therapeutic window and/or agents that are known strong inducers or inhibitors CYP3A4/5 are prohibited. In particular, enzyme-inducing antiepileptic drugs (EIAEDs).~* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for the study.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- LEE011 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Muscle-targeted Nutritional Therapy for the Recovery From COVID-19

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Sarcopenia (revised European Working Group on Sarcopenia in Older People criteria)~* Recent discharge from hospital for COVID-19~* Informed consent~Exclusion Criteria:~* Any malignant disease during the last five years~* Known kidney failure (previous glomerular filtration rate \<30 ml/min);~* Known liver failure (Child B or C)~* Psychiatric disease~* Endocrine disorders associated with disorders of calcium metabolism (excluding osteoporosis)~* Indications related to the study product:~More than 10 µg (400 IU) of daily Vitamin D intake from medical sources. More than 500 mg of daily calcium intake from medical sources. Adherence to a high energy or high protein diet up or use of protein containing or amino acid containing nutritional supplements up to three months before starting the study.~* Known allergy to milk, milk products or other components of the proposed interventions~* Indication to or ongoing artificial nutrition support~* Inclusion in other nutrition intervention trials~* Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements~* Refusal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Muscle-target oral nutritional supplementation (Type: EXPERIMENTAL): Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, and 800 IU vitamin D

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life in Patients Post Radiofrequency Ablation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 5-18 years of age~* English is the primary language~* Scheduled for an ablation at Children's Healthcare of Atlanta~* Normally structured heart~Exclusion Criteria:~* Congenital heart defect~* English is not the primary language~* Children with significant neurocognitive deficits as determined by the investigator

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Golimumab Plus UVB-311nm in Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Patients with psoriatic arthritis who receive treatment with golimumab~* Patient wish for treatment of psoriatic skin lesions~Exclusion Criteria:~* Pregnancy or lactation~* Presence and/or history of malignant melanoma~* Presence and/or history of invasive squamous cell carcinoma of the skin~* Presence and/or history of more than 3 basal cell carcinomas~* Dysplastic nevus syndrome~* Antinuclear antibodies (ds-DNA, Ro/SSA, La/SSB)~* Autoimmune disorders such as lupus erythematosus or dermatomyositis~* Abnormal photosensitivity and photosensitive diseases such as porphyria, chronic actinic dermatitis, Xeroderma pigmentosum, basal cell nevus syndrome, and others~* General poor health status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Do Patients With Skin Psoriasis Have Sub-clinical Features of Active Psoriatic Arthritis on Musculoskeletal UltraSound?

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Psoriasis by a dermatologist~* Aged 18 or more~* Reasonable fluency of spoken English~Exclusion Criteria:~* Existing diagnosis of Psoriatic arthritis~* Currently on biologics for treatment of their skin Psoriasis (as this would potentially treat and thereby diminish joint symptoms associated with PsA)~* Aged \<18years old (the study focusses on an adult population)~* Currently in prison (would be unable to attend the study ultrasound scan)~* Unable to give written consent for a musculoskeletal ultrasound e.g. advanced dementia, learning difficulties (may be unable to appreciate the reason for the study and may be unable to tolerate sitting relatively still for an ultrasound scan for 60 minutes)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- skin psoriasis participants (Type: OTHER): Single arm study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Fluid Management Based on Pleth Variability Index (PVI) Monitoring During High-risk Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults patients underwent high-risk surgery~* obtained the written informed consent~* patients under general anesthesia and mechanical ventilation~Exclusion Criteria:~* Patients with cardiac arrhythmias~* Patients \< 18 years~* Patients with a body mass index \> 40~* Patients undergoing surgery with an open thorax, neurosurgery or emergency surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: ACTIVE_COMPARATOR): Intervention group will receive hydroxyethylstarch 6% bolus in order to minimize and maintain PVI below 14 %.
- Control group (Type: NO_INTERVENTION): Control group will receive fluid at the discretion of the anesthetist

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PEMF Therapy to Treat Lingering Symptoms of Lyme Disease After Treatment With Antibiotics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis from GP confirming Lyme disease and/or~* Blood test confirming Lyme disease and/or~* Symptoms that correlate to Lyme disease without diagnosis from GP. This is called self diagnosis and because 80% of the trial is focused on treating symptoms and not the spirochetes, bacteria or small cysts of Lyme disease, the results are expected to be largely the same~Exclusion Criteria:~* Persons currently undergoing antibiotic treatment for Lyme or other conditions~* Persons who were prescribed antibiotics but did not or could not take them

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PEMF Therapy (Type: EXPERIMENTAL): Pulsed ElectroMagnetic Field Therapy using square wave forms. In addition to set, pre-defined frequencies to aid the body's own immune system, the Artificial Intelligence incorporated into the software used will suggest a variety of frequencies to be administered during treatment. Due to the software's selection, these recommendations or selections from the software will likely be different in each treatment session.
- Control (Type: NO_INTERVENTION): Control group will not receive treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Study of Hemorrhoid Surgery Using the Enseal Device to Standard Hemorrhoid Surgical Techniques

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women between ages 18 through 80~* American Society of Anesthesiologists (ASA) level I, II and III~* External hemorrhoids must be present and deemed sufficiently symptomatic to warrant removal~* Internal hemorrhoids at least Grade II~* Must be able to be seen post-operatively by the surgeon at 3 to 4 weeks and 3 months after surgery~Exclusion Criteria:~* American Society of Anesthesiologists (ASA) level IV~* Grade I internal hemorrhoids~* Currently receiving coumadin, plavix, or other anticoagulants~* No prior sphincterotomy, drainage of abscess, fistulotomy, or similar procedures~* No pregnant women at the time of surgery~* No lactating women~* No inflammatory bowel disease~* No history of chronic, active hepatitis B, C, or HIV infection~* No prior chronic narcotic use (more than 30 days)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EnSeal Device (Type: EXPERIMENTAL): EnSeal Trio Tissue Sealing Device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues